É. Sbidian

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

Léa Hoisnard, Bénédicte Lebrun‐Vignes, Sébastien Maury et al. · Scientific Reports · 2022 · 145 citations · Full text

Immunotoxicology, Immunology, Pathology +21

Mortality Associated with Neurofibromatosis 1: A Cohort Study of 1895 Patients in 1980-2006 in France

T.A. Duong, É. Sbidian, L. Valeyrie‐Allanore et al. · Orphanet Journal of Rare Diseases · 2011 · 134 citations · Full text

Association Between Mediterranean Anti-inflammatory Dietary Profile and Severity of Psoriasis

C. Phan, Mathilde Touvier, Emmanuelle Kesse‐Guyot et al. · JAMA Dermatology · 2018 · 120 citations · Full text

Antihypertensive Drugs and COVID-19 Risk

Laura Semenzato, Jérémie Botton, Jérôme Drouin et al. · Hypertension · 2021 · 113 citations · Full text

Hypertension, Cardiovascular Pharmacology, Pharmacotherapy +22

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Léa Hoisnard, Laura Pina Vegas, Rosemary Dray‐Spira et al. · Annals of the Rheumatic Diseases · 2022 · 113 citations